Recent Advances in Crystalline Polymorphism Research in Drug Development

This recorded webinar explores recent advances in pharmaceutical development by introducing NGK’s infrared crystal screening technology and Professor Etsuo Yonemochi’s research on crystalline polymorphism and morphology.

NGK Corporation is a Japan based global materials manufacturer with more than 100 years of expertise in advanced ceramics, supporting a wide range of industries including electronics and life sciences. In the first part of this recorded webinar, NGK introduces its newly launched crystal polymorphism screening service, which applies the company’s infrared radiation technology. By employing infrared radiation as a novel screening approach, the service aims to increase the likelihood of discovering previously unknown crystalline forms, thereby contributing to more robust and reliable pharmaceutical development. Several recent experimental case studies are presented to highlight the potential of this technology.

In the second part, Professor Etsuo Yonemochi (School of Pharmaceutical Sciences, Narita Campus, International University of Health and Welfare) delivers an invited lecture on pharmaceutical crystal morphology. He discusses how crystallization conditions influence crystal habit and how crystal morphology affects dissolution behavior, wettability, and manufacturability, along with examples of applying molecular simulations to evaluate formulation-related properties.